Albany,New York,USA,Jan 31
GBI Research, the leading business intelligence provider, has released its latest research Diabetes Therapeutics Market in India to 2018 Rapid Uptake of DPP-IV Inhibitors, GLP-1 Agonists and Expanding Insulin Segment to Drive Growth, which provides insights into the India anti-diabetes market until 2018. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Researchs team of industry experts. The report provides an in-depth analysis type 1 and type 2 diabetes.
The report provides an in-depth analysis on oral anti-diabetics agents, insulin products and drivers and barriers that could significantly impact the overall anti-diabetes market during the forecast period. Additionally, it explores the competitive landscape, including benchmarking the top companies in the market and the key issues and trends that are likely to have an impact on the Indian diabetes market during the forecast period.
To Buy The Copy Of This Report visit: http://www.marketresearchreports.biz/analysis-details/diabetes-therapeutics-market-in-india-to-2018-rapid-uptake-of-dpp-iv-inhibitors-glp-1-agonists-and-expanding-insulin-segment-to-drive-growth
GBI Researchs analysis revealed that the overall anti-diabetes market in India was worth $680.3m in 2011 and is projected to grow at a CAGR of 11.3% between 2011 and 2018 to reach $1,446m in 2018. High and growing diabetes population in the country, rising obese and geriatric population, and rapid market adoption of drugs from the classes such as Dipeptidyl Peptidase 4 (DPP-4) inhibitors, Glucagon-Like Peptide (GLP)-1, Sodium-Glucose Transport Proteins (SGLT-1) and others would drive the anti-diabetes market in the forecast period.
The R&D product pipeline for DM, dominated by OAD agents, consists of around 200 molecules at various stages of clinical development. Paradoxically, type 2 diabetes therapeutics market, crowded with many generics and branded generics drug products, is being seen as a significant growth opportunity for new patent protected products owing to high prevalence, progressive nature of the disease and considerably high unmet needs. Of overall R&D pipeline molecules, more than 90% are being studied for the treatment of type 2 DM.
Data and analysis on the Indian diabetes therapeutics market
Annualized market data for the diabetes therapeutics market from 2004 to 2011, with forecasts to 2018 for type 1 and type 2 diabetes.
Epidemiological data on type 1 and type 2 diabetes along with market size, annual cost of therapy, unmet needs and economic burden of diabetes.
Key drivers and restraints that have had a significant impact on the market.
Major trends and issues which are likely to have a significant impact on overall diabetes therapeutics market in India
Reasons to buy
Align their product portfolio to the markets with high growth potential.
Build effective strategies to launch their pipeline products by identifying potential geographies.
Exploit in-licensing and out-licensing opportunities by identifying products that might fill their portfolio gaps.
Develop key strategic initiatives by studying the key strategies of top competitors.
Devise a more tailored country strategy through the understanding of key drivers and barriers and market potential.
To Read The Complete Report with TOC Visit: http://www.marketresearchreports.biz/analysis/160070
For More Information Kindly Contact:
90 State Street, Suite 700
Albany, NY 12207
ListFree.org: Embedded data.